Continuing Positive Results for Imaging of Endometriosis with ⁹⁹ᵐTc-Maraciclatide

London, UK, 7 June 2024. Serac Healthcare Limited (“Serac Healthcare” or “the Company”), a clinical radiopharmaceutical company developing an innovative molecular imaging agent, and the Nuffield Department of Women’s and Reproductive Health at the University of Oxford announce that further data has been presented from the “Detecting Endometriosis expressed integrins using technetium-99m” (DETECT) imaging study, indicating that 99mTc-maraciclatide is capable of imaging superficial peritoneal endometriosis, the earliest stage of the disease. The data is being presented in a poster today by Dr Tatjana Gibbons, an investigator on the study from the University of Oxford, at the 7th European Endometriosis Congress taking place from 6-8 June 2024 in Bucharest, Romania.

Share this article with a friend

Create an account to access this functionality.
Discover the advantages